Levetiracetam safety profiles and tolerability in epilepsy patients.

@article{Briggs2004LevetiracetamSP,
  title={Levetiracetam safety profiles and tolerability in epilepsy patients.},
  author={Deborah E Briggs and Jacqueline A. French},
  journal={Expert opinion on drug safety},
  year={2004},
  volume={3 5},
  pages={415-24}
}
This review discusses the safety and tolerability of levetiracetam, as presented by the available literature, with attention paid to special populations. In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14.8 versus 8.4%), asthenia (14.7 versus 9.1%), infection (primarily common cold) (13.4 versus 7.5%), and dizziness (8.8 versus 4.1%). Adverse events usually appear within the first month after treatment… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Open - label studies have added patient data with other epileptic syndromes and from a wider patient pool , such as children and patients with prior psychiatric history .
Open - label studies have added patient data with other epileptic syndromes and from a wider patient pool , such as children and patients with prior psychiatric history .
In Phase II / III trials , the adverse effects occurring more commonly in the treatment groups versus the placebo group were ; somnolence ( 14.8 versus 8.4% ) , asthenia ( 14.7 versus 9.1% ) , infection ( primarily common cold ) ( 13.4 versus 7.5% ) , and dizziness ( 8.8 versus 4.1% ) .
EpilepsyMay be treated byLevetiracetam
Levetiracetam safety profiles and tolerability in epilepsy patients .
In Phase II / III trials , the adverse effects occurring more commonly in the treatment groups versus the placebo group were ; somnolence ( 14.8 versus 8.4% ) , asthenia ( 14.7 versus 9.1% ) , infection ( primarily common cold ) ( 13.4 versus 7.5% ) , and dizziness ( 8.8 versus 4.1% ) .
All Topics